Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8893476 | 0.93 | FAAH (0.33) | FAAHMGLLKMT2ASMN1; SMN2 | |
| SCHEMBL8539509 | 0.79 | — | — | |
| SCHEMBL8629338 | 0.78 | MGLL (0.41) | FAAHMGLLKMT2ASMN1; SMN2PTGER4 | |
| SCHEMBL21575529 | 0.78 | MGLL (0.41) | FAAHMGLLKMT2ASMN1; SMN2PTGER4 | |
| SCHEMBL8626067 | 0.78 | MGLL (0.41) | FAAHMGLLKMT2ASMN1; SMN2PTGER4 | |
| SCHEMBL23901063 | 0.78 | MGLL (0.41) | FAAHMGLLKMT2ASMN1; SMN2PTGER4 | |
| SCHEMBL8632296 | 0.78 | MGLL (0.41) | FAAHMGLLKMT2ASMN1; SMN2PTGER4 | |
| SCHEMBL23901147 | 0.78 | MGLL (0.41) | FAAHMGLLKMT2ASMN1; SMN2PTGER4 | |
| SCHEMBL21648859 | 0.78 | MGLL (0.41) | FAAHMGLLKMT2ASMN1; SMN2PTGER4 | |
| SCHEMBL8829436 | 0.78 | MGLL (0.41) | FAAHMGLLKMT2ASMN1; SMN2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013456-A1 | FORMULATIONS OF BENZAZEPINE CONJUGATES AND USES THEREOF | Silverback Therapeutics, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021072203-A1 | TGFBETAR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072330-A1 | GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210077632-A1 | Formulations of Benzazepine Conjugates and Uses Thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| WO-2021030665-A1 | FORMULATIONS OF BENZAZEPINE CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077632-A1 | Formulations of Benzazepine Conjugates and Uses Thereof | BDNF, FURIN, VGF | FAAH 396/4885MGLL 1700/4885KMT2A 1199/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | FAAH 3841/4885MGLL 3998/4885KMT2A 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.